Yazici Yusuf
New York University Schoolof Medicine, NYU Hospital for Joint Diseases, 333 East 38th Street,New York, NY 10016, USA.
Bull NYU Hosp Jt Dis. 2012;70 Suppl 1:11-3.
The current approach to treatment of RA includes early and aggressive treatment with routine monitoring of outcomes to give patients the best chance of decreasing disease activity as much as possible, with low disease activity and remission being a realistic goal for many patients. In this quest, DMARDs, especially MTX, are the anchor treatment, and low dose prednisone should also be considered in combination with MTX as the best initial choice for RA treatment. Current data suggest that corticosteroids are disease modifying agents that enhance the effects of DMARDs with no real impact on adverse events. We are much better positioned now then in earlier times to provide a good outcome for our patients, and every available tool needs to be considered and utilized for this purpose.
目前类风湿关节炎（RA）的治疗方法包括早期积极治疗，并对治疗结果进行常规监测，以使患者尽可能获得降低疾病活动度的最佳机会，低疾病活动度和病情缓解是许多患者切实可行的目标。在这一过程中，改善病情抗风湿药（DMARDs），尤其是甲氨蝶呤（MTX），是基础治疗药物，低剂量泼尼松也应与MTX联合使用，作为RA治疗的最佳初始选择。目前的数据表明，皮质类固醇是改善病情的药物，可增强DMARDs的疗效，且对不良事件无实际影响。与早期相比，我们现在更有条件为患者提供良好的治疗效果，为此需要考虑并利用每一种可用的工具。
